Advanced statistical tools can help with navigation through numerous biomarkers, combining individual and distinct features into more relevant groups–e.g., consensus molecular subtypes classification of CRC as a prognostic and predictive instrument for clinical decisions [25,26,27] Factors, once associated only with poor prognosis, lead researchers to new therapy development (e.g., BRAF, HER2) [28]. The gene discussed is ERBB2; the disease is colorectal carcinoma.